Investigator:
Mark Dunne (PI), mark.j.dunne@manchester.ac.uk
Indi Banerjee, indi.banerjee@manchester.ac.uk
Summary:
NIHR funded second stage study to study phenotypes of hypoglycaemia to understand impact on neonatal brain
Indi Banerjee (PI), indi.banerjee@manchester.ac.uk
Dose finding multicentre trial of insulin receptor antibody (Xoma 358) [pending acquisition issues]
Dr Pratik Shah (PI), Pratik.Shah@gosh.nhs.uk
XOMA 358 is a fully human allosteric modulating monoclonal antibody that binds to insulin receptors and attenuates insulin action.
Personalized diagnosis and treatment of congenital hyperinsulinemia caused by beta-cell pathology- A new imaging technique for more sensitive and specific pre-operative imaging of focal CHI. The imaging technique is a PET/CT scan with radioactive 68Ga-exendin-4.
Dr Kathryn Beardsall, kb274@medschl.cam.ac.uk
Both high and low blood sugar levels are common in preterm babies and this has been linked with poor outcome. One of the difficulties of managing sugar levels in preterm babies is that it involves a sample of blood being taken and as clinical teams try to avoid disturbing babies there is often a long time between measurements. There is now a device which monitors and records sugar levels continuously (continuous glucose monitor) which is used by some children and adults with diabetes. This involves a small sensor being placed under the skin which can be left for up to a week and allows the patient to respond quickly and treat changes in their sugar levels.
REACT will be studying the effectiveness of using continuous glucose monitoring in 200 preterm babies to see if it can help reduce how often and for how long they have very high or very low sugar levels.
https://vimeo.com/224488826/133526077c
http://paediatrics.medschl.cam.ac.uk/research/clinical-trials/real-time-continuous-glucose-monitoring-newborn-react/